(Q53256103)

12 May 2018

title

Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. (English)

1 reference

12 May 2018

1 reference

5

Despland PA

1 reference

12 May 2018

author name string

Genton P

1

1 reference

12 May 2018

Sadzot B

2

1 reference

12 May 2018

Fejerman N

3

1 reference

12 May 2018

Peltola J

4

1 reference

12 May 2018

Steinhoff B

6

1 reference

12 May 2018

Rektor I

7

1 reference

12 May 2018

Wroe S

8

1 reference

12 May 2018

Maubrey MC

9

1 reference

12 May 2018

Vandervelden C

10

1 reference

12 May 2018

van Hammée G

11

1 reference

12 May 2018

Schlit AF

12

1 reference

12 May 2018

van Paesschen W

13

1 reference

12 May 2018

language of work or name

English

0 references

publication date

1 June 2006

1 reference

12 May 2018

Acta Neurologica Scandinavica

published in

1 reference

12 May 2018

volume

113

1 reference

12 May 2018

issue

6

1 reference

12 May 2018

page(s)

387-394

1 reference

12 May 2018

Revisiting the concept of identifiable neurons

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

Long-term continuation of levetiracetam in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

10.1111/J.1600-0404.2006.00647.X

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018